Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

As the number of cancer survivors continues to grow, research investigating the factors that affect cancer outcomes, such as disease recurrence, risk of second malignant neoplasms, and the late effects of cancer treatments, becomes ever more important. Numerous epidemiologic studies have investigated factors that affect cancer risk, but far fewer have addressed the extent to which demographic, lifestyle, genomic, clinical, and psychosocial factors influence cancer outcomes. To identify research priorities as well as resources and infrastructure needed to advance the field of cancer outcomes and survivorship research, the National Cancer Institute sponsored a workshop titled "Utilizing Data from Cancer Survivor Cohorts: Understanding the Current State of Knowledge and Developing Future Research Priorities" on November 3, 2011, in Washington, DC. This commentary highlights recent findings presented at the workshop, opportunities to leverage existing data, and recommendations for future research, data, and infrastructure needed to address high priority clinical and research questions. Multidisciplinary teams that include epidemiologists, clinicians, biostatisticians, and bioinformaticists will be essential to facilitate future cancer outcome studies focused on improving clinical care of cancer patients, identifying those at high risk of poor outcomes, and implementing effective interventions to ultimately improve the quality and duration of survival.

[1]  M. Relling,et al.  Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  X. Shu,et al.  Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project , 2012, Breast Cancer Research and Treatment.

[3]  A. Berrington de González,et al.  Converting Epidemiologic Studies of Cancer Etiology to Survivorship Studies: Approaches and Challenges , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[4]  J. Meyerhardt,et al.  Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Kahn,et al.  Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. , 2012, Journal of the National Cancer Institute.

[6]  Jeffrey Hoch,et al.  Is knowledge translation adequate? A quality assurance study of staging investigations in early stage breast cancer patients , 2012, Breast Cancer Research and Treatment.

[7]  I. Lossos,et al.  LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era , 2012, Leukemia & lymphoma.

[8]  L. Allen,et al.  C-B2-01: Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network , 2011, Clinical Medicine & Research.

[9]  T. Ahern,et al.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. , 2011, Journal of the National Cancer Institute.

[10]  F. V. van Leeuwen,et al.  Methods to Assess Adverse Health-Related Outcomes in Cancer Survivors , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[11]  Angela B Mariotto,et al.  Cancer Survivors: A Booming Population , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[12]  E. Paskett,et al.  Cancer Survivorship Research: A Review of the Literature and Summary of Current NCI-Designated Cancer Center Projects , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[13]  S. Bhatia.  Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[14]  S. Nass,et al.  A National Cancer Clinical Trials Network: Recommendations From the Institute of Medicine , 2011, American journal of therapeutics.

[15]  A. Skol,et al.  Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma , 2011, Nature Medicine.

[16]  G. Hortobagyi,et al.  Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221) , 2011, Breast Cancer Research and Treatment.

[17]  Marianne Lundkjær Gjerstorff,et al.  The Danish Cancer Registry , 2011, Scandinavian journal of public health.

[18]  X. Shu,et al.  The After Breast Cancer Pooling Project: rationale, methodology, and breast cancer survivor characteristics , 2011, Cancer Causes & Control.

[19]  C. Earle,et al.  Preventive care in prostate cancer patients: following diagnosis and for five-year survivors , 2011, Journal of cancer survivorship : research and practice.

[20]  L. Natarajan,et al.  Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.

[21]  J. Cerhan,et al.  Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Sternfeld,et al.  Associations of physical activity with quality of life and functional ability in breast cancer patients during active adjuvant treatment: the Pathways Study , 2011, Breast Cancer Research and Treatment.

[23]  K. Lunetta,et al.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. , 2011, Journal of the National Cancer Institute.

[24]  C. Rock,et al.  Soy Food Consumption and Breast Cancer Prognosis , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[25]  T. Trikalinos,et al.  Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer , 2011, Annals of Internal Medicine.

[26]  G. Hortobagyi,et al.  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer , 2010, Clinical Cancer Research.

[27]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[28]  C. Ulrich,et al.  Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation , 2010, Journal of the National Cancer Institute.

[29]  J. Cerhan,et al.  Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Okunieff,et al.  Testicular cancer survivorship: research strategies and recommendations. , 2010, Journal of the National Cancer Institute.

[31]  C. Ulrich,et al.  Use of Folic Acid–Containing Supplements after a Diagnosis of Colorectal Cancer in the Colon Cancer Family Registry , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[32]  Wendy Leisenring,et al.  Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. , 2010, Journal of the National Cancer Institute.

[33]  B. Christensen,et al.  Breast Cancer DNA Methylation Profiles Are Associated with Tumor Size and Alcohol and Folate Intake , 2010, PLoS genetics.

[34]  J. Cerhan,et al.  Smoking, alcohol use, obesity, and overall survival from non‐Hodgkin lymphoma , 2010, Cancer.

[35]  G. Hortobagyi,et al.  Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer , 2010, Breast Cancer Research and Treatment.

[36]  J. Cerhan,et al.  Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Ji-Yeob Choi,et al.  Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Martino,et al.  Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial , 2009, Clinical Cancer Research.

[39]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[40]  D. Wickerham,et al.  Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group , 2009, Journal of cancer survivorship : research and practice.

[41]  John D Boice,et al.  The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Hall,et al.  Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Sherman,et al.  Complementary and alternative therapy use before and after breast cancer diagnosis: the Pathways Study , 2009, Breast Cancer Research and Treatment.

[44]  B. Sternfeld,et al.  The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California , 2008, Cancer Causes & Control.

[45]  C. Ulrich,et al.  Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Christiani,et al.  A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies , 2008, Cancer Epidemiology Biomarkers & Prevention.

[47]  Loki Natarajan,et al.  Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. , 2007, JAMA.

[48]  J. Cerhan,et al.  Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. , 2007, Blood.

[49]  D. Neuberg,et al.  MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Hall,et al.  Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Steve Scoppa,et al.  Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2007, Cancer Epidemiology Biomarkers & Prevention.

[52]  Bingshu E. Chen,et al.  Risk of second non-hematological malignancies among 376,825 breast cancer survivors , 2007, Breast Cancer Research and Treatment.

[53]  C. Ulrich,et al.  New Developments in the Epidemiology of Cancer Prognosis: Traditional and Molecular Predictors of Treatment Response and Survival , 2006, Cancer Epidemiology, Biomarkers and Prevention.

[54]  Kevin C Oeffinger,et al.  Chronic health conditions in adult survivors of childhood cancer. , 2006, The New England journal of medicine.

[55]  J. Perlmutter,et al.  From Cancer Patient to Cancer Survivor: Lost in Translation , 2006 .

[56]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[57]  W. Willett,et al.  Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort , 2005, BMJ : British Medical Journal.

[58]  Joel E Tepper,et al.  Increased risk of rectal cancer after prostate radiation: a population-based study. , 2005, Gastroenterology.

[59]  Kevin C Oeffinger,et al.  Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2003, JAMA.

[60]  T. Hartge,et al.  Textbook of Cancer Epidemiology , 2003 .

[61]  N. Heerema,et al.  Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. , 2002, Blood.

[62]  M. Stovall,et al.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Greene,et al.  Solid tumors after chronic lymphocytic leukemia. , 2001, Blood.

[64]  H. Storm,et al.  Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[66]  Terry L. Smith,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. , 1998, Lancet.

[67]  B. Kohler,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[68]  B. Hankey,et al.  Second malignant neoplasms among long-term survivors of ovarian cancer. , 1996, Cancer research.

[69]  S. Wacholder,et al.  Second cancers among long-term survivors of non-Hodgkin's lymphoma. , 1993, Journal of the National Cancer Institute.

[70]  B. Sternfeld,et al.  Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project , 2011, Breast Cancer Research and Treatment.

[71]  R. Hoover,et al.  New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. , 2006 .

[72]  A. Tichelli,et al.  Considerations for adult cancer survivors. , 2005, Hematology. American Society of Hematology. Education Program.